Grufity logo
Grufity logo

Latest Affinity Asset Advisors, LLC Stock Portfolio

$1.94Billion | No. of Holdings #92

Affinity Asset Advisors, LLC Performance

2026 Q1+9.21%
YTD+9.21%
2025+46.96%

About Affinity Asset Advisors, LLC and 13F Hedge Fund Stock Holdings

Affinity Asset Advisors, LLC is a hedge fund based in New York, NY. On 2026-05-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Affinity Asset Advisors, LLC reported an equity portfolio of $1.9 Billions as of 31 Mar, 2026. <br><br> The top stock holdings of Affinity Asset Advisors, LLC are , XENE, ERAS. The fund has invested 5.6% of it's portfolio in APOGEE THERAPEUTICS INC and 5% of portfolio in XENON PHARMACEUTICALS INC. <br><br> The fund managers got completely rid off VENTYX BIOSCIENCES INC (VTYX), TANGO THERAPEUTICS INC (TNGX) and ARCUS BIOSCIENCES INC (RCUS) stocks. They significantly reduced their stock positions in TAYSHA GENE THERAPIES INC (TSHA), CULLINAN THERAPEUTICS INC (CGEM) and BRIDGEBIO PHARMA INC (BBIO). Affinity Asset Advisors, LLC opened new stock positions in ENLIVEN THERAPEUTICS INC, DAMORA THERAPEUTICS INC (GLTO) and TYRA BIOSCIENCES INC (TYRA). The fund showed a lot of confidence in some stocks as they added substantially to PERSPECTIVE THERAPEUTICS INC, COMPASS PATHWAYS PLC (CMPS) and BELITE BIO INC (BLTE).
Affinity Asset Advisors, LLC Equity Portfolio Value
Last Reported on: 14 May, 2026
$1.94Billion
  as of May 14, 2026

Affinity Asset Advisors, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that Affinity Asset Advisors, LLC made a return of 9.21% in the last quarter. In trailing 12 months, it's portfolio return was 80.51%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
enliven therapeutics inc23,006,600
helix acquisition corp iii12,700,000
damora therapeutics inc11,655,000
alto neuroscience inc11,240,000
tyra biosciences inc9,862,710
korro bio inc8,002,150
crispr therapeutics ag7,135,500
spyglass pharma inc6,477,500
New stocks bought by Affinity Asset Advisors, LLC

Additions

Ticker% Inc.
perspective therapeutics inc954
cogent biosciences inc600
compass pathways plc454
eupraxia pharmaceuticals inc429
belite bio inc225
ascendis pharma a/s216
dianthus therapeutics inc204
arrowhead pharmaceuticals in185
Additions to existing portfolio by Affinity Asset Advisors, LLC

Reductions

Ticker% Reduced
taysha gene therapies inc-69.7
cullinan therapeutics inc-59.56
bridgebio pharma inc-53.12
establishment labs hldgs inc-50.00
immunovant inc-50.00
wave life sciences ltd-48.08
climb bio inc-46.15
karyopharm therapeutics inc-43.79
Affinity Asset Advisors, LLC reduced stake in above stock

Sold off

Ticker$ Sold
travere therapeutics inc-9,989,000
ventyx biosciences inc-58,555,600
geron corp-1,980,000
tango therapeutics inc-8,860,000
arcus biosciences inc-7,149,000
avadel pharmaceuticals plc-5,387,500
mersana therapeutics inc-2,893,000
ultragenyx pharmaceutical in-1,725,000
Affinity Asset Advisors, LLC got rid off the above stocks

Sector Distribution

Affinity Asset Advisors, LLC has about 73.2% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare73.2
Others26.8

Market Cap. Distribution

Affinity Asset Advisors, LLC has about 15% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • UNALLOCATED
  • LARGE-CAP
  • SMALL-CAP
  • MICRO-CAP
Category%
MID-CAP39.9
UNALLOCATED26.8
LARGE-CAP15
SMALL-CAP11.7
MICRO-CAP5.7

Stocks belong to which Index?

About 43.4% of the stocks held by Affinity Asset Advisors, LLC either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
Index%
Others56.6
RUSSELL 200043.4
Top 5 Winners (%)%
ERAS
erasca inc
199.2 %
q32 bio inc
93.4 %
STRO
sutro biopharma inc
83.5 %
MGNX
macrogenics inc
77.3 %
ACLX
arcellx inc
64.4 %
Top 5 Winners ($)$
ERAS
erasca inc
57.6 M
AGLE
spyre therapeutics inc
24.0 M
ACLX
arcellx inc
22.0 M
XENE
xenon pharmaceuticals inc
19.5 M
CNTA
centessa pharmaceuticals plc
14.7 M
Top 5 Losers (%)%
WVE
wave life sciences ltd
-43.6 %
lexeo therapeutics inc
-37.4 %
VRDN
viridian therapeutics inc
-37.1 %
VRCA
verrica pharmaceuticals inc
-36.3 %
RCKT
rocket pharmaceuticals inc
-35.4 %
Top 5 Losers ($)$
WVE
wave life sciences ltd
-20.0 M
lexeo therapeutics inc
-17.3 M
abivax sa
-10.7 M
mineralys therapeutics inc
-6.8 M
INSM
insmed inc
-4.9 M

Affinity Asset Advisors, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Affinity Asset Advisors, LLC

Affinity Asset Advisors, LLC has 92 stocks in it's portfolio. About 37.3% of the portfolio is in top 10 stocks. WVE proved to be the most loss making stock for the portfolio. ERAS was the most profitable stock for Affinity Asset Advisors, LLC last quarter.

$1.71BTotal Value
104Positions
14 May, 2026Last Reported
Current holdings of Current Stock Holdings of Affinity Asset Advisors, LLC, last reported on 14 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ASND
Ascendis Pharma A/S

Ascendis Pharma A/S

ASND
Affinity Asset Advisors, LLC's holding in Ascendis Pharma A/S over time
1.12%95,000
$21.73M
1.12%
increased 216.67 percentadded
BLTE
Belite Bio Inc

Belite Bio Inc

BLTE
Affinity Asset Advisors, LLC's holding in Belite Bio Inc over time
0.54%65,000
$10.36M
0.54%
increased 225 percentadded
CMPS
Compass Pathways Plc

Compass Pathways Plc

CMPS
Affinity Asset Advisors, LLC's holding in Compass Pathways Plc over time
0.32%1,108,480
$6.13M
0.32%
increased 454.24 percentadded